Literature DB >> 19088256

Tumor necrosis factor-alpha upregulates 11beta-hydroxysteroid dehydrogenase type 1 expression by CCAAT/enhancer binding protein-beta in HepG2 cells.

Irena D Ignatova1, Radina M Kostadinova, Christopher E Goldring, Andrea R Nawrocki, Felix J Frey, Brigitte M Frey.   

Abstract

The enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) catalyzes the conversion of inactive to active glucocorticoids. 11beta-HSD1 plays a crucial role in the pathogenesis of obesity and controls glucocorticoid actions in inflammation. Several studies have demonstrated that TNF-alpha increases 11beta-HSD1 mRNA and activity in various cell models. Here, we demonstrate that mRNA and activity of 11beta-HSD1 is increased in liver tissue from transgenic mice overexpressing TNF-alpha, indicating that this effect also occurs in vivo. To dissect the molecular mechanism of this increase, we investigated basal and TNF-alpha-induced transcription of the 11beta-HSD1 gene (HSD11B1) in HepG2 cells. We found that TNF-alpha acts via p38 MAPK pathway. Transient transfections with variable lengths of human HSD11B1 promoter revealed highest activity with or without TNF-alpha in the proximal promoter region (-180 to +74). Cotransfection with human CCAAT/enhancer binding protein-alpha (C/EBPalpha) and C/EBPbeta-LAP expression vectors activated the HSD11B1 promoter with the strongest effect within the same region. Gel shift and RNA interference assays revealed the involvement of mainly C/EBPalpha, but also C/EBPbeta, in basal and only of C/EBPbeta in the TNF-alpha-induced HSD11B1 expression. Chromatin immunoprecipitation assay confirmed in vivo the increased abundance of C/EBPbeta on the proximal HSD11B1 promoter upon TNF-alpha treatment. In conclusion, C/EBPalpha and C/EBPbeta control basal transcription, and TNF-alpha upregulates 11beta-HSD1, most likely by p38 MAPK-mediated increased binding of C/EBPbeta to the human HSD11B1 promoter. To our knowledge, this is the first study showing involvement of p38 MAPK in the TNF-alpha-mediated 11beta-HSD1 regulation, and that TNF-alpha stimulates enzyme activity in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19088256     DOI: 10.1152/ajpendo.90531.2008

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  22 in total

1.  G6PT-H6PDH-11βHSD1 triad in the liver and its implication in the pathomechanism of the metabolic syndrome.

Authors:  Ibolya Czegle; Miklós Csala; József Mandl; Angelo Benedetti; István Karádi; Gábor Bánhegyi
Journal:  World J Hepatol       Date:  2012-04-27

2.  Interaction of adenosine 3',5'-cyclic monophosphate and tumor necrosis factor-alpha on serum amyloid A3 expression in mouse granulosa cells: dependence on CCAAT-enhancing binding protein-beta isoform.

Authors:  Deok-Soo Son; Paul F Terranova; Katherine F Roby
Journal:  Endocrinology       Date:  2010-05-05       Impact factor: 4.736

3.  Decreased 11β-hydroxysteroid dehydrogenase 1 in lungs of steroid receptor coactivator (Src)-1/-2 double-deficient fetal mice is caused by impaired glucocorticoid and cytokine signaling.

Authors:  Jingfei Chen; Ritu Mishra; Yaqin Yu; Jeffrey G McDonald; Kaitlyn M Eckert; Lu Gao; Carole R Mendelson
Journal:  FASEB J       Date:  2020-10-18       Impact factor: 5.191

4.  Hepatic inflammation induced by high-fructose diet is associated with altered 11βHSD1 expression in the liver of Wistar rats.

Authors:  Ana Vasiljević; Biljana Bursać; Ana Djordjevic; Danijela Vojnović Milutinović; Marina Nikolić; Gordana Matić; Nataša Veličković
Journal:  Eur J Nutr       Date:  2014-01-04       Impact factor: 5.614

5.  IL-6 mediates 11βHSD type 2 to effect progression of the mycobacterial cord factor trehalose 6,6'-dimycolate-induced granulomatous response.

Authors:  April N Abbott; Kerry J Welsh; Shen-An Hwang; Paulina Płoszaj; Tina Choudhury; Sydney Boyd; Michael R Blackburn; Robert L Hunter; Jeffrey K Actor
Journal:  Neuroimmunomodulation       Date:  2011-03-08       Impact factor: 2.492

6.  Elevated hepatic 11β-hydroxysteroid dehydrogenase type 1 induces insulin resistance in uremia.

Authors:  Ananda Chapagain; Paul W Caton; Julius Kieswich; Petros Andrikopoulos; Nanda Nayuni; Jamie H Long; Steven M Harwood; Scott P Webster; Martin J Raftery; Christoph Thiemermann; Brian R Walker; Jonathan R Seckl; Roger Corder; Muhammad Magdi Yaqoob
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-25       Impact factor: 11.205

7.  Regulation of 11β-HSD1 expression during adipose tissue expansion by hypoxia through different activities of NF-κB and HIF-1α.

Authors:  Jong Han Lee; Zhanguo Gao; Jianping Ye
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-03-19       Impact factor: 4.310

Review 8.  Pathogenesis of hepatic steatosis: the link between hypercortisolism and non-alcoholic fatty liver disease.

Authors:  Giovanni Tarantino; Carmine Finelli
Journal:  World J Gastroenterol       Date:  2013-10-28       Impact factor: 5.742

Review 9.  11β-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action.

Authors:  Karen Chapman; Megan Holmes; Jonathan Seckl
Journal:  Physiol Rev       Date:  2013-07       Impact factor: 37.312

10.  Hepatic cysteine sulphinic acid decarboxylase depletion and defective taurine metabolism in a rat partial nephrectomy model of chronic kidney disease.

Authors:  Nima Abbasian; Maryam Ghaderi-Najafabadi; Emma Watson; Jeremy Brown; Li Yu Si; Debbie Bursnall; Izabella Pawluczyk; Anne-Marie Seymour; Alan Bevington
Journal:  BMC Nephrol       Date:  2021-07-05       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.